WATERTOWN, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development
of RNAi-based therapeutics, today announced that members of the
management team will present at two upcoming conferences:
Bernstein Emerging Biotech Conference 2014, Snowbird, Utah:
Douglas M. Fambrough, Ph.D., Chief Executive Officer, to present on
Tuesday, March 11, 2014 at 5:40 P.M.
BIO-Europe Spring® 2014 Conference in
Turin, Italy: James B. Weissman, Chief Business Officer, to
participate in a panel discussion titled, "Dealmaking strategies
around orphan diseases," on Monday, March 10 at 1:30 P.M. and to
present on Tuesday, March 11 at 4:45 P.M.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and
development of innovative treatments for rare inherited diseases
involving the liver and for cancers that are genetically defined.
Dicerna is using its proprietary RNA interference (RNAi) technology
platform to build a broad pipeline in these therapeutic areas and
intends to discover, develop and commercialize novel therapeutics either
on its own or in collaboration with pharmaceutical partners.
Dicerna Pharmaceuticals, Inc.
James B. Weissman,
Chief Business Officer
Chris Erdman, 781-235-3060
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media